Lenvatinib Pill,Paclitaxel

Phase 2

NNational Health Research Institutes, Taiwan

Lenvatinib Pill,Paclitaxel is one of 3 therapeutic programs targeting Advanced Biliary Tract Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Advanced Biliary Tract CancerActive, not recruiting

Advanced Biliary Tract CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Advanced Biliary Tract Cancer

#DrugCompanyPhaseTrials

Lenvima

Eisai

Phase 2

1 2

Mfolfox6

Roche

Phase 2

1 3

Lenvatinib Pill,Paclitaxel

NNational Health Research Institutes, Taiwan

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Active, not recruiting

Advanced Biliary Tract Cancer

NCT05170438

Clinical

Trials by Indication[1]

Advanced Biliary Tract Cancer1 trial

Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment

Active, not recruiting·NNational Health Research Institutes, Taiwan·Phase 2·NCT05170438·51 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lenvatinib Pill,Paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Lenvatinib Pill,Paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Health Research Institutes, Taiwan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: NNational Health Research Institutes, Taiwan

Lenvatinib Pill,Paclitaxel

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Advanced Biliary Tract Cancer1 trial

References

Drug Info

Quick Facts

Related News